You would appreciate that it’s very difficult to forecast the new variant outlook and it seems that this winter will be winter of many different variants. Some of them will be less active or some of them Evusheld can be less or more active, because we are definitely continuing to work with regulators and governments to collect and provide the data. On your second question on the — our new Evusheld to zero and next generation of the long acting monoclonal antibodies, I think this really speaks to our commitment to the immunocompromised patient, and we are doing our best to accelerate the development and delivery of the new Evusheld. Currently we are in the preclinical development and we are — we believe that we will be able to bring it to the patient at the end of the next year.
Pascal Soriot: Thank you, Iskra. Andrew, just maybe to add, I think it’s important to remember at the end of the day, what matters is the clinical activity. And then sometimes we see reduced activity in laboratory studies. But in fact, in real life, what we have seen so far is continued high level of protection, especially against severe disease with this antibody, it continues to be active. And as — and we haven’t had any concerns expressed by authorities so far. And as Iskra was explaining, those variants, they changed a lot. And we see in some countries new variants emerged that are very contagious, that are actually sensitive to Evusheld. So this situation can change the other way around very rapidly. So it is really hard to predict.
On the Farxiga font, I mean, you’re right to say that we have a strong commercial organization. And I think we’re all very proud of the work the team has done around the world and a primary care organization that has the strengths that we have is quite rare in the industry actually. And beyond primary care, we have strengths in nephrology, in cardiology and diabetology and that positions us well to do business development activities. But as it relates to the specific case that you mentioned, as you can imagine, I cannot answer. The only thing I can tell you is that we certainly continue to look at potential business development opportunities that fit with therapy areas of focus, and where we could add value to our expertise and also importantly, our global commercial network.
So we’ll move to the next one. Tim Anderson at Wolfe.
Timothy Anderson: All right. Thank you. Enhertu in the U.S a big a big quarter. Was that all demand driven? or was there some stocking embolus? And then is it unrealistic to think that global peak sales of the molecule could surpass the Tagrisso peak at some point well into the future? And then a second question on PPI litigation for a long time Astra had that joint venture with Merck, the Astra-Merck joint venture. Is any potential financial liability that you face shared with Merck because of that? And if so, are the parties in dispute in any aspect of this?
Pascal Soriot: Sorry, Tim, can you repeat the second question? So we make sure we have got it correctly.
Timothy Anderson: Yes. So my question is just on the PPI litigation. So you used to have the Astra-Merck joint venture. I’m wondering if there’s any shared liability.
Pascal Soriot: Okay. Got it. Got it. David, do you want to cover the first one?
